Most of the confusion in this area comes from a single conflation: the question of maintenance treatment: what happens after the first six sessions looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. Anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants.
Every the United States programme is operating inside the same clinical framework, which runs as follows. Comparing clinics is difficult because the variables that matter are not the ones displayed on the website. Two facilities can charge similar prices and offer materially different care. The questions that separate them are who is physically present during the session and what their credential is, whether monitoring is continuous or intermittent, how the dose is determined and whether it is adjusted between sessions, what the plan is if a person does not respond after the induction course, whether psychiatric care is coordinated with an existing prescriber, and what integration support exists. Those answers can be obtained in one phone call, and the willingness to give them plainly is itself informative.
How the pieces fit together in practice
Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. In the United States the same rule applies: acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. That is as true in the United States as anywhere else in the country. Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved.
Set aside the United States for a moment, because the general position comes first. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
The underlying facts, stated once and clearly
Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Nothing about the United States changes that. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. Patients researching the United States providers run into this constantly. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing.
Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
Safety, screening and the limits of the evidence
A single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. The the United States listings on this page are organised so that this is checkable rather than assumed. If the neuroplasticity hypothesis is right, what happens between sessions is not an optional extra but part of how the treatment is meant to function. For anyone weighing options in the United States, the gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. Anyone comparing the United States programmes will find this decisive: the clinicians running these programmes come from anaesthesiology, psychiatry, emergency medicine and pain management, and the route shapes how the treatment is framed. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
What varies between providers and why it matters
A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. It is the first thing to establish about any the United States programme. That holds in the United States as it does everywhere: a separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. It is worth carrying that into every conversation with a the United States provider. Applied to the United States, the point is this: an anaesthesiologist and a psychiatrist offering the same infusion are often running quite different programmes around it.
Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
What to do next
The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. Read against the the United States market, a standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two.
Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Putting this to use
Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. That is as true in the United States as anywhere else in the country. A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. The useful framing is that what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit. That holds in the United States as it does everywhere: ketamine acts on the glutamate system rather than the monoamine pathways targeted by conventional antidepressants, which is the likely reason its timeline differs so sharply. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.